WE’RE CELEBRATING.
A NEW ANTIBODY
FAILED TO FAIL.
The US FDA has granted a Breakthrough Therapy designation to the first anti-TIGIT
therapy for use in NSCLC in combination with PD-L1 blockade. TIGIT expression in
paraffin-embedded non-small cell lung cancer is observed using TIGIT (E5Y1W) XP®
Rabbit mAb #99567.
OUR PROCESS — YOUR SUCCESS.
As a privately held company founded and led by
active research scientists, we understand your
needs as a researcher. Like you, we only want to use
products that are specific and deliver reproducible
results. We validate every one of our thousands of
antibodies and research products in-house. If any
product fails to meet our stringent standards, we
won’t sell it. But when one passes, it’s a big deal. For
over 20 years, researchers have trusted CST to help
them achieve experimental success. You can, too.
www.cellsignal.com
© 2022 Cell Signaling Technology, Inc. Cell Signaling Technology, CST, and XP are trademarks or registered trademarks of Cell Signaling Technology, Inc. 22-BCH-13880-MAR22
RNI TC No. MAHENG14628 RNI NO. DELENG/2004/13061
Date of Publication - 30.4.2022 Date of Posting - 1.5.2022
The words you are searching are inside this book. To get more targeted content, please make full-text search by clicking here.
Indian biopharma industry HITS Rs 33K Cr WITH 13% GROWTH
Amidst the pandemic, the Indian Biopharma Industry, with over 300 companies, has witnessed a good growth of 13 per cent, 2 percent less than the previous year’s 15 percent growth rate. This growth was largely driven by performance of the Indian biopharma companies which have done very well as against multinational companies. As a result,the Indian Biopharma Industry has crossed the Rs 33,000 crore mark for the year 2020-21 over the previous year’s figure of Rs 29,176 crore. The Indian Biopharma industry, comprising hormones, insulin, blood products and vaccines recorded a
sales revenue of Rs 33,067 crore for
the year 2020-21.
Discover the best professional documents and content resources in AnyFlip Document Base.
Search